albumin binding raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-14 and is reviewed periodically as new material appears.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Reconstituted solutions are less stable than the dry powder, and stability depends on concentration, pH, buffer composition, and container material. Low-protein-binding tubes reduce loss of peptide to plastic surfaces. Some researchers add a carrier protein to limit adsorption at low concentrations. The exact shelf life of a given solution is best determined empirically through a stability study rather than assumed from general guidance, because published data cover only a limited set of conditions.
Storage conditions for semaglutide depend heavily on the presentation. Lyophilized research powder is generally kept at two to eight degrees Celsius in a sealed container, protected from light and moisture. Manufacturer labeling for finished injectable products specifies refrigeration before first use, with defined in-use periods at room temperature afterward. The oral tablet form is stored at controlled room temperature and is more tolerant of short excursions. Temperature excursions should be documented rather than inferred.
Peptide degradation follows several routes. Hydrolysis cleaves the backbone at susceptible residues, oxidation targets methionine and tryptophan side chains, and aggregation produces higher-molecular-weight species that are difficult to reverse. Light exposure accelerates oxidation, which is why amber glass or opaque secondary packaging is common. Repeated freeze-thaw cycles promote aggregation and are best avoided. Stability-indicating methods detect these changes before they become visible.
=== Personal care and homecare === Surfactants are used in detergents, washing-up liquids, shampoos, shower gels, and similar products to increase the “solubility” of fat and dirt particles that adhere to laundry or the body in water. Fabric softeners can consist of cationic surfactants that prevent laundry from becoming stiff when dry.
Ketamine is a cyclohexanone-derived dissociative general anesthetic and NMDA receptor antagonist with analgesic and hallucinogenic properties, used medically for anesthesia, depression, and pain management. Ketamine exists as its two enantiomers, S- (esketamine) and R- (arketamine), and has antidepressant action likely involving NMDA antagonism as well as other mechanisms. At anesthetic doses, ketamine induces a state of dissociative anesthesia, a trance-like state providing pain relief, sedation, and amnesia. Its distinguishing features as an anesthetic are preserved breathing and airway reflexes, stimulated heart function with increased blood pressure, and moderate bronchodilation. As an anesthetic, it is used especially in trauma, emergency, and pediatric cases. At lower, sub-anesthetic doses, it is used as a treatment for pain and treatment-resistant depression. Ketamine is legally used in medicine but is also tightly controlled, as it is used as a recreational drug for its hallucinogenic and dissociative effects. When used recreationally, it is found both in crystalline, powder and liquid form, and is often referred to by users as "Ket", "Special K" or simply "K". The long-term effects of repeated use are largely unknown and are an area of active investigation. Liver and urinary toxicity have been reported among regular users of high doses of ketamine for recreational purposes. Ketamine can cause dissociation and nausea, and other adverse effects, and is contraindicated in severe heart or liver disease, and uncontrolled psychosis.
=== Fortification === In the early 1930s, the United States and countries in northern Europe began to fortify milk with vitamin D in an effort to eradicate rickets. This, plus medical advice to expose infants to sunlight, effectively ended the high prevalence of rickets. The proven health benefit of vitamin D led to fortification to many foods, even foods such as hot dogs and beer. In the 1950s, due to some highly publicized cases of hypercalcemia and birth defects, vitamin D fortification became regulated, and even discontinued in some countries. As of 2024, governments have established mandated or voluntary food fortification programs to combat deficiency in, respectively, 15 and 10 countries. Depending on the country, manufactured foods fortified with either D2 or D3 may include dairy milk and other dairy foods, fruit juices and fruit juice drinks, meal replacement food bars, soy-protein–based beverages, wheat flour or corn meal products, infant formulas, breakfast cereals and 'plant milks',.
=== Relationship to Nazism and antisemitism === Various statements made by Jung in the 1930s have been cited as evidence of both contempt and sympathy for Nazism. In 1933, after the Nazis gained power in Germany, Jung became the president of the new International General Medical Society for Psychotherapy (Allgemeine Ärztliche Gesellschaft für Psychotherapie); the professional body aimed to have affiliated organizations in different countries. The German affiliated organization was the Deutsche Allgemeine Ärztliche Gesellschaft für Psychotherapie, led by Matthias Göring, an Adlerian psychotherapist, and a cousin of the prominent Nazi Hermann Göring, excluded Jews. In 1933, the society's journal, Zentralblatt für Psychotherapie, published a statement endorsing Nazi positions, and Hitler's book Mein Kampf. Jung's response to this was twofold. In "The State of Psychotherapy Today", published in 1934 in the Zentralblatt für Psychotherapie, Jung wrote: "The Aryan unconscious has a greater potential than the Jewish unconscious" and "The Jew, who is something of a nomad, has never yet created a cultural form of his own and as far as we can see never will".
Sources: en.wikipedia.org
The activity of the cell is regulated by extracellular signals. Signal propagation inside and/or along the interior of cells depends on PPIs between the various signaling molecules. The recruitment of signaling pathways through PPIs is called signal transduction and plays a fundamental role in many biological processes and in many diseases including Parkinson's disease and cancer.
WHO recommends assigning hazard classes to all MNMs according to the Globally Harmonized System (GHS) of Classification and Labelling of Chemicals for use in safety data sheets. For a limited number of MNMs this information is made available in the guidelines (strong recommendation, moderate-quality evidence). WHO recommends updating safety data sheets with MNM-specific hazard information or indicating which toxicological end-points did not have adequate testing available (strong recommendation, moderate-quality evidence). For the respirable fibres and granular biopersistent particles' groups, the GDG suggests using the available classification of MNMs for provisional classification of nanomaterials of the same group (conditional recommendation, low-quality evidence). B. Assess exposure to MNMs
=== Ho–Hu === Gladys Lounsbury Hobby (1910–1993), American microbiologist known for development and early understanding of antibiotics Dorothy Hodgkin (1910–1994), British chemist, 1964 Nobel Prize in chemistry for development of protein crystallography Jacobus Henricus van 't Hoff (1852–1911), Dutch physical chemist known for developing the princioles of chemical thermodynamics, 1901 Nobel Prize in Chemistry Albert Hofmann (1906–2008), Swiss chemist, synthesized Lysergic acid diethylamide (LSD) August Wilhelm Hofmann (1818–1892), German chemist, first to isolate sorbic acid Darleane C. Hoffman (1926–2025), American nuclear chemist who studied the properties of transuranium elements Friedrich Hoffmann (1660–1742), German physician and chemist who found that lime, magnesia, etc. existed in almost all mineral springs in Germany Roald Hoffmann (born 1937), Polish-born American chemist, 1981 Nobel Prize in Chemistry for theories of the course of chemical reactions Antonín Holý (1936–2012), Czech medicinal chemist known for acyclic nucleoside phosphonates, including Cidofovir, Adefovir and Tenofovir Mei Hong (born 1970), Chinese-American biophysical chemist known for development solid-state nuclear magnetic resonance to elucidate the structures and mechanisms of membrane proteins Frederick Gowland Hopkins (1861–1947), British biochemist, known for discovery of vitamins, Nobel Prize in Physiology or Medicine in 1929 Marjorie G.
Sources: en.wikipedia.org
=== Muscular origin === Myopathic origin BSS can be secondary to various muscular disorders or occur as a primary idiopathy. These etiologies are termed secondary and primary BSS respectively. Idiopathic primary BSS is a late-onset myopathy with progressive muscular weakness that is detected on the spinal extensor muscles in elderly patients and is more predominant in females. The pathogenesis of primary BSS is typically related to fibrosis and fatty infiltration of muscular tissues and to mitochondrial changes due to the aging process. Specifically, weakening occurs in the paravertebral muscles of patients. These paravertebral muscles have a great influence over the walking stance and gait of a patient, so fatty infiltration and degradation of these muscle lead to the characteristics that easily define BSS, such as the anterior flexion of the back combined with an ability to keep upright with any kind of support (e.g., holding onto a table). Secondary BSS can have a multitude of causes, making it hard to pinpoint to a specific muscular disorder. Some examples of diseases that have secondary BSS as a symptom are myopathies caused by muscular dystrophies, neuromuscular disorders, and inflammatory muscle diseases; metabolic or endocrine disorders; and mitochondrial myopathies.
1993/3156) European Communities (Definition of Treaties) (European Investment Fund) Order 1993 (S.I. 1993/3157) Drug Trafficking Offences Act 1986 (Designated Countries and Territories) (Amendment) (No. 2) Order 1993 (S.I. 1993/3158) Environment and Safety Information (Northern Ireland) Order 1993 (S.I. 1993/3159) Roads (Northern Ireland) Order 1993 (S.I. 1993/3160) Merchant Shipping (Fire Protection) (Non-United Kingdom) (Non-SOLAS Ships) (Amendment) Rules 1993 (S.I. 1993/3161) Merchant Shipping (Fire Appliances) (Amendment) Regulations 1993 (S.I. 1993/3162) Merchant Shipping (Fire Protection) (Amendment) Regulations 1993 (S.I. 1993/3163) Merchant Shipping (Fire Protection) (Ships Built Before 25 May 1980) (Amendment) Regulations 1993 (S.I. 1993/3164) Water and Sewerage Services (Amendment) (Northern Ireland) Order 1993 (S.I. 1993/3165) Ministerial and other Salaries Order 1993 (S.I. 1993/3166) Redundancy Payments (National Health Service) (Modification) Order 1993 (S.I. 1993/3167) Finance Act 1985 (Interest on Tax) (Prescribed Rate) (No. 2) Order 1993 (S.I. 1993/3168) Local Government Act 1992 (Commencement No. 3) Order 1993 (S.I. 1993/3169) Town and Country Planning (Fees for Applications and Deemed Applications) (Amendment) Regulations 1993 (S.I. 1993/3170) Taxes (Interest Rate) (Amendment No. 4) Regulations 1993 (S.I. 1993/3171) National Health Service (General Dental Services) Amendment (No. 2) Regulations 1993 (S.I. 1993/3172) Commercial Agents (Council Directive) (Amendment) Regulations 1993 (S.I.
== Production == Lithium carbonate is made from primarily two sources: spodumene and petalite ores, and underground brine pools. About 82,000 tons were produced in 2020, showing significant and consistent growth.
Tachykinin peptides are one of the largest families of neuropeptides, found from amphibians to mammals. They were so named due to their ability to rapidly induce contraction of gut tissue. The tachykinin family is characterized by a common C-terminal sequence, Phe-X-Gly-Leu-Met-NH2, where X is either an Aromatic or an Aliphatic amino acid. The genes that produce tachykinins encode precursor proteins called preprotachykinins, which are chopped apart into smaller peptides by posttranslational proteolytic processing. The genes also code for multiple splice forms that are made up of different sets of peptides. Tachykinins excite neurons, evoke behavioral responses, are potent vasodilators, and contract (directly or indirectly) many smooth muscles. Tachykinins are from ten to twelve residues long. The two human tachykinin genes are called TAC1 and TAC3 for historical reasons, and are equivalent to Tac1 and Tac2 of the mouse, respectively. TAC1 encodes neurokinin A (formerly known as substance K), neuropeptide K (which has also been called neurokinin K), neuropeptide gamma, and Substance P. Alpha, beta, and gamma splice forms are produced; the alpha form lacks exon 6 and the gamma form lacks exon 4. All three splice forms of TAC1 produce substance P, but only the beta and gamma forms produce the other three peptides. Neuropeptide K and neuropeptide gamma are N-terminally longer versions of neurokinin A that appear to be final peptide products in some tissues. TAC3 encodes neurokinin B. The best known tachykinin is Substance P.
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.